Musculoskeletal oncology, also referred to as orthopedic oncology, is a highly specialized branch of orthopedic surgery. Musculoskeletal oncology is used in treatment of sculoskeletal cancers and tumors.
Bone and soft tissue tumors are quite rare and sometimes require reconstructive surgery. Soft tissue sarcomas are more common than bone sarcomas. For 2016, the American Cancer Society estimates about 3,300 new cases for cancer of the bones and joints, and 12,310 new cases for soft tissue sarcomas.
There are three main types of bone cancers –
- Osteosarcoma, which arises most often in the growing ends of long bones;
- Chondrosarcoma, which develops in the metaphysis;
- Ewing’s sarcoma.
Chondrosarcoma is more prevalent than other forms of cancer and swift diagnosis and effective treatment remains a challenge for health providers. Treatment with chemotherapy and radiotherapy is not the only way to treat the disease. Therefore, adequate surgical resection is the mainstay of treatment in case of chondrosarcoma. Patients with chronic renal impairment may be more likely to have a history of heart disease.
Request Free Report Sample @ http://www.futuremarketinsights.com/reports/sample/rep-gb-1572
Radiofrequency ablation has become the standard and most preferred choice of treatment in case of osteoma osteoma, a benign bone tumor that arises from osteoblasts. However, studies demonstrate its expanded application in palliative treatment of patients with painful bone metastasis. The ability to perform less invasive procedures often allows more efficient, less painful, and more cost-effective patient care. In addition, minimally invasive techniques, such as kyphoplasty, vertebroplasty, and acetabuloplasty may provide an alternative to major reconstructive surgery for patients with metastatic disease.
Global Musculoskeletal Oncology Therapeutics Market: Drivers & Restraints
One of the most important factors in the development of cancer is cancer. Patients who had high-dose external radiation therapy or treatment with anti-cancer drugs are at higher risk of developing osteosarcoma. However, a small number of bone cancers are also due to heredity defects of bones; People with metal implants, what doctors are using to repair fractures, are more likely to develop osteosarcoma. In case of soft tissue sarcoma, adults with heredity disorders such as retinoblastoma, tuberous sclerosis, and Werner syndrome are at a higher risk of developing this type of cancer.
Development of safe and effective treatment procedures has also bolstered the growth of the musculoskeletal oncology therapeutics market. For example, image-guided surgery systems, primarily used in joints reconstruction, have been applied to orthopedic oncology. This may be a good idea for the patient, but the patient is not able to do so. Thus, increasing focus of orthopedic oncologists to integrate advances in the surgical techniques by collaboration with subspecialties is to be expected to boost the growth of the market during the forecast period, 2016-2026.
Unwanted complications associated with the radiation therapy, such as increased risk of wound complications and post-radiation fractures is hampering the musculoskeletal oncology therapeutics market growth. Additionally, high cost associated with the treatment and lack of awareness of the effective treatment therapies.
Request For TOC @ http://www.futuremarketinsights.com/toc/rep-gb-1572
Global Musculoskeletal Oncology Therapeutics Market: Segmentation
Musculoskeletal oncology therapeutics marketis on the basis of diagnosis, treatment, end-user, and geography.
- By Diagnosis
- X- Ray
- Magnetic resonance imaging (MRI) scan
- Computed tomography (CT) scan
- Positron emission tomography (PET) scan
- Biopsy
- By Treatment
- Surgery
- amputation
- Limb Salvage Surgery
- Reconstructive Surgery
- Chemotherapy
- Radiation Therapy
- Immunotherapy
- Targeted Therapy
- Surgery
- By End User
- Multispecialty Hospitals
- Cancer Research Institute
- Diagnostic Centers
Global Musculoskeletal Oncology Therapeutics Market: Overview
In the past few years, significant advances have been made in treatment of musculoskeletal oncology related disorders. Yet, there is an urgent need to develop more sophisticated and highly advanced techniques to best manage hard-to-treat osteosarcomas.
Rising prevalence of musculoskeletal disorders is the most common cause of cancer. Owing to these factors, the musculoskeletal oncology therapeutics market is expected to grow at a healthy rate.
Global Musculoskeletal Oncology Therapeutics Market: Region-wise Outlook
On the basis of regional presence, musculoskeletal oncology therapeuticsmarket is segmented into seven key regions: North America, Latin America, and Eastern Europe, Western Europe, and Asia pacific excluding Japan (APEJ), Japan, Middle East and Africa. Europe and North America are the largest markets for musculoskeletal oncology therapeutics, owing to increased R & D investments and high levels of awareness among end-users. Asia pacific represents immense growth opportunity for musculoskeletal oncology therapeutics market, owing to high population and increase in the prevalence of cancer.
Global Musculoskeletal Oncology Therapeutics Market: Key Players
Key market players in the musculoskeletal oncology therapeutics market are Stryker Corporation, Accentus Inc., Roche Diagnostics, Amgen Inc., Novartis AG, Biogen dec, GlaxoSmithKline, Sanofi SA, and Pfizer Inc.
Browse Full Report @ http://www.futuremarketinsights.com/reports/musculoskeletal-oncology-therapeutics-market